Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-10-03
2002-04-09
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S486000, C424S488000
Reexamination Certificate
active
06369037
ABSTRACT:
TECHNICAL FIELD
This invention is directed at a composition for the controlled release of doxorubicin.
BACKGROUND OF THE INVENTION
Doxorubicin is a commonly used antineoplastic drug. Commonly responsive tumors include acute leukemia, Hodgkin's disease, other lymphoinas, breast and lung cancer. Doxorubicin has been reported to give a high response rate in the treatment of advanced breast cancer and to give favorable results for the treatment of gastric carcinoma (a tumor for which only four drugs are known to be active). However, doxorubicin has a narrow therapeutic index and causes cardiac toxicity at a cumulative dose of 450 to 550 mg/m
2
. The usual dosage is 40-75 mg/m
2
rapidly intravenous or 30 mg/m
2
for three days by continuous IV. Alternative methods of administration have been sought which accommodate the narrow therapeutic index and cumulative dose toxicity. In particular, a controlled release form of doxorubicin has been sought, and glutaraldehyde treated erythrocytes and glutaraldehyde treated albumin have been suggested as carriers for this purpose. However, the glutaraldehyde can react with the doxorubicin causing the doxorubicin to become less active and is potentially toxic, and heat is used in glutaraldehyde treatment of albumin which can inactivate doxorubicin. Accordingly, a carrier for controlled release of doxorubicin has been sought where no chemical cross-linker is necessary and where beat is not involved in the preparation of the carrier.
SUMMARY OF THE INVENTION
The invention herein provides a composition for the controlled release of doxorubicin where the carrier is a dextran-methacrylate biodegradable hydrogel and where no chemical cross-linker or heat are necessary for the preparation of the carrier. The composition for the controlled release of doxorubicin comprises doxorubicin physically entrapped in a dextran-methacrylate biodegradable hydrogel. The composition is formed, for example, by photocrosslinking dextran methacrylate monoester in solution in a medium containing doxorubicin and drying, the dextran methacrylate monoester having an average degree of substitution of each &agr;-D-glucopyranosyl of dextran by methacrylic acid ranging from 0.05 to 0.75 and a weight average molecular weight ranging from 40,000 to 80,000 on a dextran basis, e.g., 50,000 to 75,000 on a dextran basis, said medium being buffered to a pH ranging from 2 to 8, the weight ratio of doxorubicin to dextran methacrylate monoester ranging from 1:200 to 1:2000, e.g., from 1:500 to 1:1500.
In one subset of the invention, the dextran methacrylate monoester which is photocrosslinked has an average degree of substitution ranging from 0.05 to 0.15.
In another subset of the invention, the dextran methacrylate monoester which is photocrosslinked has an average degree of substitution ranging from 0.15 to 0.40.
In still another subset of the invention, the dextran methacrylate monoester which is photocrosslinked has an average degree of substitution ranging from 0.40 to 0.75.
The term “physically entrapped” is used herein to mean physically impregnated, i.e., the drug is within the hydrogel network but there has been no chemical reaction between the drug and the hydrogel network.
The term “hydrogel” is used herein to mean a polymeric material which exhibits the ability to swell in water and to retain a significant portion of water within its structure without dissolution.
The term “biodegradable hydrogel” is used herein mean hydrogel formed by cross-linking a polymer which is degraded by water and/or by enzymes found in the body.
The term “photocrosslinking” is used herein to mean causing vinyl bonds in the methacryloyl moieties to break and form cross-links by the application of radiant energy.
The term “degree of substitution” is used herein to mean the number of hydroxyl groups in a glucose unit of &agr;-D-glucopyranosyl moiety of dextran that form ester group with methacrylic acid. Since each said glucose unit contains three hydroxyl groups, the maximum degree of substitution is 3.0. The average degree of substitution connotes the average degree of substitution based on all the glucose units in the molecules of dextran methacrylate monoester.
The term “on a dextran basis” is used herein to mean that the weight average molecular weight referred to is that of the dextran starting material for preparing the dextran methacrylate monoester which provides the dextran moiety of the dextran methacrylate monoester. The weight average molecular weights referred to herein are those determined on dextran by light scattering or gel permeation chromatography. In the working example herein, the dextran used to prepare the dextran methacrylate monoester was obtained from Sigma Chemicals, and had a weight average molecular weight of 70,000 determined by gel permeation chromatography; therefore, the dextran methacrylate monoester used in the working example herein had a weight average molecular weight of 70,000 on a dextran basis, determined by gel permeation chromatography.
REFERENCES:
patent: 4925677 (1990-05-01), Feijen
patent: 5334640 (1994-08-01), Desai et al.
patent: 5514379 (1996-05-01), Weissleder et al.
patent: 5700848 (1997-12-01), Soon-Shiong et al.
patent: 5736161 (1998-04-01), de los Santos Garces et al.
patent: 5846530 (1998-12-01), Soon-Shiong et al.
Kim, S., et al., J. Biomed. Mater. Res. 49(4), 517-527 (3/2000).
Kim, S., et al., J. Biomaterials Applications 15(1), 23-46 (7/2000).
Matherne, C. M., et al., Am. J. Vet. Res. 55, No. 6, 847-853 (6/94).
Tonetti, M., et al., Am. J. Vet. Res. 52, No. 10, 1630-1635 (10/91).
Arap, W., et al., Science 279, 377-380 (1/98).
Gupta, P. K., et al., Life Sciences 46, 471-479 (1990).
Park, K., et al., Biodegradable Hydrogels for Drug Delivery, Technomic Publishing Co., Inc., Lancaster, Pa, 85-87 (1993).
van Dijk-Wolthuis, W. N. E., Macromolecules 30, 4639-4645 (1997).
Graham, N. B., et al., Biomaterials 5, 27-36 (1/84).
Hennink W. E., et al., J. Control. Release 39, 47-55 (1996).
Franssen, O., et al., J. Control. Release 44, 237-245 (1997).
Jones, C., et al., J. Pharm. Pharmacol. 41, 813-816 (6/89).
Chu Chih-Chang
Kim Sin-Hee
Cornell Research Foundation Inc.
Peselev Elli
LandOfFree
Controlled release of doxorubicin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release of doxorubicin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release of doxorubicin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2824571